In the latest trading session,, 0.5 million Denali Therapeutics Inc (NASDAQ:DNLI) shares changed hands as the company’s beta touched 1.33. With the company’s most recent per share price at $14.38 changing hands around $0.28 or 1.99% at last look, the market valuation stands at $2.09B. DNLI’s current price is a discount, trading about -131.78% off its 52-week high of $33.33. The share price had its 52-week low at $10.57, which suggests the last value was 26.5% up since then. When we look at Denali Therapeutics Inc’s average trading volume, we note the 10-day average is 1.62 million shares, with the 3-month average coming to 1.61 million.
Analysts gave the Denali Therapeutics Inc (DNLI) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.06. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended DNLI as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight.
Denali Therapeutics Inc (NASDAQ:DNLI) trade information
Instantly DNLI is in green as seen in intraday trades today. With action 5.58%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -34.64%, with the 5-day performance at 5.58% in the green. However, in the 30-day time frame, Denali Therapeutics Inc (NASDAQ:DNLI) is 6.20% up. Looking at the short shares, we see there were 11.95 million shares sold at short interest cover period of 7.92 days.
The consensus price target for the stock as assigned by Wall Street analysts is 32, meaning bulls need an upside of 55.06% from its recent market value. According to analyst projections, DNLI’s forecast low is 32 with 32 as the target high. To hit the forecast high, the stock’s price needs a -122.53% plunge from its current level, while the stock would need to soar -122.53% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -4.46%. The 2025 estimates are for Denali Therapeutics Inc earnings to decrease by -18.33%, but the outlook for the next 5-year period is at 4.56% per year.
DNLI Dividends
Denali Therapeutics Inc is expected to release its next quarterly earnings report on 2025-May-06.
Denali Therapeutics Inc (NASDAQ:DNLI)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 9.97% of Denali Therapeutics Inc shares while 94.28% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 104.72%. There are 94.28% institutions holding the Denali Therapeutics Inc stock share, with BAILLIE GIFFORD & CO the top institutional holder. As of 2024-06-30, the company held 8.1523% of the shares, roughly 13.76 million DNLI shares worth $319.59 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 7.8034% or 13.17 million shares worth $305.91 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 7.97 shares estimated at $114.47 million under it, the former controlled 5.49% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.58% of the shares, roughly 3.76 shares worth around $53.93 million.
